Sg3 Management, LLC Chemo Centryx, Inc. Put Options Transaction History

Sg3 Management, LLC

$0
Q3 2023

Put Options

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $460,800 - $825,300	30,000 New	30,000 $743,000
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $613,272 - $1.08 Million	-27,600 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$18.38 - $40.5 $1.59 Million - $3.51 Million	-86,600 Reduced 75.83%	27,600 $1.01 Million
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $307,094 - $462,038	-23,300 Reduced 16.95%	114,200 $1.95 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $1.18 Million - $6.26 Million	123,100 Added 854.86%	137,500 $1.84 Million
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $772,668 - $1.07 Million	-15,600 Reduced 52.0%	14,400 $738,000
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $1.42 Million - $1.95 Million	-30,000 Reduced 50.0%	30,000 $1.86 Million
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $1.62 Million - $2.16 Million	35,000 Added 140.0%	60,000 $3.29 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $964,500 - $1.63 Million	25,000 New	25,000 $1.44 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.